New findings on morning sickness treatment
The randomized, controlled study recruited pregnant women who had experienced severe NVP or hyperemesis gravidarum (HG) - an extreme form of morning sickness - in a previous pregnancy. These women were instructed either to start using Diclectin(R) before NVP symptoms appeared (the pre-emptive group), or to start Diclectin(R) at the first sign of NVP symptoms (the control group). The severity of NVP symptoms was compared between the two groups.
Results demonstrate that women who started using Diclectin(R) before NVP symptoms began had significantly reduced symptoms of severe NVP compared to women who only started Diclectin(R) when NVP symptoms appeared. In the pre-emptive group, there were 70% fewer cases of moderate-to-severe NVP compared to the control group during the 3 first weeks of NVP (p=0.05). Pre-emptive use of Diclectin(R) was also found to decrease the recurrence of HG in women with a previous history of HG (p=0.047).
"Women with NVP commonly report feeling unsupported by the medical community, and many physicians and pharmacists are hesitant to prescribe anti-emetics to pregnant women," said lead researcher Dr. Gideon Koren. "These new, important data continue to prove that NVP is a serious medical condition, and drive awareness of safe and effective treatment options to alleviate NVP symptoms and possibly prevent extreme cases of hyperemesis gravidarum."
The delayed release combination of 10 mg doxylamine and 10 mg pyridoxine has been shown to be safe and effective in more than 200,000 pregnant women.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.